Related Experiment Video

Updated: Mar 30, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM

Nicholas B Argento, Katherine Nakamura

    Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    |November 3, 2015
    PubMed
    Abstract

    Insights

    Canagliflozin (CANA) use in type 1 diabetes (T1D) significantly improved glycemic control, reduced weight and blood pressure, and lowered insulin needs. While generally safe, some patients experienced side effects like infections or ketoacidosis.

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Limited data exists on the long-term effects of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes (T1D).
    • Continuous glucose monitoring (CGM) provides valuable insights into glycemic variability and treatment efficacy.

    Purpose of the Study:

    • To evaluate the chronic effects of canagliflozin (CANA) on glycemic control, weight, and blood pressure in patients with type 1 diabetes.
    • To assess the safety and tolerability of canagliflozin as an adjunct therapy in T1D.

    Main Methods:

    • Retrospective review of 27 type 1 diabetes patients using Dexcom G4 Platinum continuous glucose monitors for over a year.
    • Analysis of CGM data before and after initiating canagliflozin 100 mg daily for at least one month.
    • Comparison with a control group of 27 patients with similar characteristics not receiving canagliflozin.

    Main Results:

    • Canagliflozin significantly reduced mean blood glucose, CGM standard deviation, time in hyperglycemia, hemoglobin A1C, weight, and systolic blood pressure.
    • Patients experienced increased time in target glucose range, with minimal hypoglycemia.
    • Total daily insulin dose was reduced, and estimated glomerular filtration rate remained stable.

    Conclusions:

    • Canagliflozin shows promise as an adjunctive therapy for managing type 1 diabetes.
    • Careful patient selection and monitoring are advised due to potential side effects such as genital mycotic infections and ketoacidosis.

    More Related Videos

    Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

    Simple Continuous Glucose Monitoring in Freely Moving Mice

    Published on: February 24, 2023

    8.6K
    Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

    Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

    Published on: March 7, 2025

    1.1K

    Related Concept Videos

    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    1.0K
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
    938
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    1.3K
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    931
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    1.3K
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    5.5K